Skip to main
KMB

Kimberly-Clark (KMB) Stock Forecast & Price Target

Kimberly-Clark (KMB) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 71%
Sell 0%
Strong Sell 7%

Bulls say

Kimberly-Clark is set to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026. Although it may face some cost pressures starting in 2Q26 due to higher oil costs and the CA warehouse fire, efforts to mitigate these costs through hedging, productivity, pricing, and marketing adjustments are in place. With a strong track record of delivering organic sales and EPS growth and a favorable cost outlook, the company is well-positioned for continued success in the tissue and hygiene market.

Bears say

Kimberly-Clark is facing potential risks to its earnings in 2027 due to spiking resin costs, which can add $300-350M to costs, impacting EPS by ~$0.70-0.80. The KVUE deal is expected to bring significant cost and synergy savings, but will initially be dilutive to EPS and may not have a significant impact until 2028. Furthermore, the company's business transformation, including the divestiture of IFP, may bring some savings in the near future, but results may be uncertain. The target price for the stock has been lowered to $114 due to increased uncertainty.

Kimberly-Clark (KMB) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 71% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kimberly-Clark and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kimberly-Clark (KMB) Forecast

Analysts have given Kimberly-Clark (KMB) a Hold based on their latest research and market trends.

According to 14 analysts, Kimberly-Clark (KMB) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kimberly-Clark (KMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.